Vernalis Research Limited

Suneel Gaur

Roger John Gillespie

Joanne Lerpiniere

Claire Elizabeth Dawson

Scott Murray Weiss

Gemma Caroline Stratton

Robert Mark Pratt

Samantha Jayne Bamford

Stefania Leonardi

David Reginald Adams

Jonathan Richard Anthony Roffey

Jonathan Mark Bentley

Richard John Hamlyn

Matthew Alexander James Duncton

Howard Langham Mansell

James Edward Paul Davidson

Ian Anthony Cliffe

Nathaniel Monck

Ashley Roger George

Lars Jacob Stray Knutsen

Simon Edward Ward

David Bebbington

Michael John Bickerdike

Michael Frederick Snape

Steven Michael McAteer

David Reginald Adoms

Pharmaceutical compositions and their uses comprising compounds of formula (I): wherein: Ris selected from: alkyl, alkoxy, aryloxy, alkylthio, arylthio, aryl, halogen, CN, NRR, NRCOR, NRCONRR, NRCOR, and NRSOR; Ris a heteroaryl attached via an unsaturated ring carbon of said heteroaryl group; Ris selected from: H, alkyl, halogen, OR, SR, and NRR; Ris selected from: H, acyclic alkyl, CONRR, CONRNRR, COR, COR, and SOR; R, R, and Rare independently selected from: H, alkyl, and aryl, or where Rand Rare in an NRRgroup, Rand Rmay be linked to form a hetero cyclic group, or where R, Rand Rare in a (CONRNRR) group, Rand Rmay be linked to form a heterocyclic group; and Ris selected from alkyl and aryl, or a pharmaceutically acceptable salt thereof.

Pyrazolo [3,4-d] pyrimidine derivatives and their use as purinergic receptor antagonists

The use of a compound of formula (I): wherein

Triazol[4,5-d] pyramidine derivatives and their use as purinergic receptor antagonists

Use of a compound of formula (I) wherein Ris selected from alkyl, aryl, alkoxy, aryloxy, 0thioalkyl, thioaryl, CN, halo, NRR, NRCOR, NRCONRR, NRCORand NRSOR; Ris selected from N, O or S-containing heteroaryl groups, wherein the heteroaryl group is attached via an unsaturated carbon atom which is adjacent to one or two N, O or S-heteroatom(s), other than ortho, ortho-disubstituted heteroaryl groups; Ris selected from H, alkyl, COR, CONRR, CONRNRR, CORand SOR; R, Rand Rare independently selected from H, alkyl and aryl or where Rand Rare in an (NRR) group then Rand Rmay be linked to form a heterocyclic ring; Ris selected from alkyl and aryl; R, Rand Rare independently selected from H, alkyl and aryl, or Rand Rmay be linked to form a heterocyclic ring, or where R, Rand Rare in a (CONRNRR) group, Rand Rmay be linked to form a heterocyclic group; and R, is selected from alkyl and aryl, or a pharmaceutically acceptable salt thereof or prodrug thereof, in the treatment or prevention of a disorder in which the blocking of purine receptors, particularly adenosine receptors and more particularly Areceptors, may be beneficial, particularly wherein said disorder is a movement disorder such as Parkinson's disease or said disorder is depression, cognitive or memory impairment, acute or chronic pain, ADHD or narcolepsy, or for neuroprotection in a subject; compounds of formula (I) for use in therapy; and novel compounds of formula (I) per se. 

Purine derivatives as purinergic receptor antagonists

Triazolo [4,5-d] pyrimidine derivatives and their use as purinergic receptor antagonists

A compound of formula (I), wherein X is S or O; Ris selected from H, alkyl, aryl, hydroxy, alkoxy, aryloxy, thioalkyl, thioaryl, halogen, CN, COR, COR, CONRR, CONRNRR, NRR, NRCONRR, NRCOR, NRCOR, and NRSOR; Ris selected from aryl attached via an unsaturated carbon atom; Ris selected from H, alkyl, hydroxy, alkoxy, halogen, CN and NO; Ris selected from H, alkyl, aryl, hydroxy, alkoxy, aryloxy, thioalkyl, thioaryl, halogen, CN, NO, COR, COR, CONRR, CONRNRR, NRR, NRCONRR, NRCOR, NRCORand NRSOR; R, Rand Rare independently selected from H, alkyl and aryl or where Rand Rare in an (NRR) group, Rand Rmay be linked to form a heterocyclic group, or where R, Rand Rare in a (CONRNRR) group, Rand Rmay be linked to form a heterocyclic group; and Ris selected from alkyl and aryl, or a pharmaceutically acceptable salt thereof or prodrug thereof, and the use thereof in therapy and in the treatment or prevention of a disorder in which the blocking of purine receptors, particularly adenosine receptors and more particularly Areceptors, may be beneficial, particularly wherein said disorder is a movement disorder such a Parkinson's disease or said disorder is depression, cognitive or memory impairment, acute or chronic pain, ADHD or narcolepsy, or wherein said medicament is for neuroprotection in a subject 

Thieno(3,2-d)pyrimidines and furano(3,2-d)pyrimidines and their use as purinergic receptor antagonists

The use of a compound of formula (I): wherein Ris selected from H, alkyl, aryl, alkoxy, aryloxy, alkylthio, arylthio, halogen, CN, NRR, NRCONR, NRCONRR,NRCORand NRSOR; Ris selected from aryl attached via an unsaturated carbon; Ris selected from H, alkyl, COR, COR, CONRR, CONRNRRand SOR; R, Rand Rare independently selected from H, alkyl and aryl or where Rand Rare in an NRRgroup, Rand Rmay be linked to form a heterocyclic group, or where R, Rand Rare in a (CONRNRR) group, Rand Rmay be linked to form a heterocyclic group; and Ris selected from alkyl and aryl, or a pharmaceutically acceptable salt thereof or prodrug thereof, in the treatment or prevention of a disorder in which the blocking of purine receptors, particularly adenosine receptors and more particularly Areceptors, may be beneficial, particularly wherein said disorder is a movement disorder such as Parkinson's disease or said disorder is depression, cognitive or memory impairment, acute or chronic pain, ADHD or narcolepsy, or for neuroprotection in a subject; compounds of formula (I) for use in therapy; and novel compounds of formula (I) per se 

Triazolo[4,5-d]pyrimidine derivatives and their use as purinergic receptor antagonists

Use of a compound of formula (I): wherein Ris selected from alkyl, alkoxy, aryloxy, alkylthio, arylthio, aryl, halogen, CN, NRR, NRCOR, NRCONRR, NRCORand NRSOR; Ris selected from heteroaryl attached via an unsaturated carbon; Ris selected from H, alkyl, halogen, OR, SRand NRR; Ris selected from H, acyclic alkyl, CONRR, CONRNRR, COR, CORand SOR; R, Rand Rare independently selected from H, alkyl and aryl, or where Rand Rare in an NRRgroup, Rand Rmay be linked to form a heterocyclic group, or where R, Rand Rare in a (CONRNRR) group, Rand Rmay be linked to form a heterocyclic group; and Ris selected from alkyl and aryl, or a pharmaceutically acceptable salt thereof or prodrug thereof, in the treatment or prevention of a disorder in which the blocking of purine receptors, particularly adenosine receptors and more particularly Areceptors, may be beneficial, particularly wherein said disorder is a movement disorder such as Parkinson's disease or said disorder is depression, cognitive or memory impairment, acute or chronic pain, ADHD or narcolepsy, or for neuroprotection in a subject; compounds of formula (I) for use in therapy; and novel compounds of formula (I) per se. 

Pyrazolo[3,4-d]pyrimidine derivatives and their use as purinergic receptor antagonists

2-adamantylethylamines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission

4-Quinolinemethanol derivatives as purine receptor antagonists (1)

A chemical compound of formula (I), wherein n is 1, 2 or 3; R and R are independently selected from hydrogen and alkyl; R is alkyl; R to R are independently selected from hydrogen, halogen, hydroxy, alkyl, aryl, alkoxy, aryloxy, alkylthio, arylthio, alkylsulfoxyl, alkylsulfonyl, arylsulfoxyl, arylsulfonyl, amino, monoalkylamino, dialkylamino, nitro, cyano, carboxaldehyde, alkylcarbonyl, arylcarbonyl, aminocarbonyl, monoalkylaminocarbonyl, dialkylaminocarbonyl, alkoxycarbonylamino, aminocarbonyloxy, monoalkylaminocarbonyloxy, dialkylaminocarbonyloxy, monoalkylaminocarbonylamino and dialkylaminocarbonylamino, or R and R together form a carbocyclic or heterocyclic ring, and pharmaceutically acceptable salts and prodrugs thereof, and the use thereof in therapy, particularly for the treatment of disorders of the central nervous system; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders, diabetes insipidus, and sleep apnea, and particularly for the treatment of obesity

Pyrroloindoles, pyridoindoles and azepinoindoles as 5-ht2c agonists

Indoline derivatives as 5-HT2B and or 5-HTC receptor ligands

Growing community of inventors

Wokingham, United Kingdom

Suneel Gaur